Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRamon y Cajal Agüeras, Santiago
dc.contributor.authorSese Faustino, Marta
dc.contributor.authorCapdevila Castillo, Clàudia
dc.contributor.authorAasen, Trond
dc.contributor.authorMattos Arruda, Leticia de
dc.contributor.authorDiaz-Cano, Salvador J.
dc.contributor.authorHernandez Losa, Javier
dc.contributor.authorCastellví Vives, Josep
dc.date.accessioned2021-10-22T05:54:06Z
dc.date.available2021-10-22T05:54:06Z
dc.date.issued2020-02
dc.identifier.citationRamón y Cajal S, Sesé M, Capdevila C, Aasen T, De Mattos-Arruda L, Diaz-Cano SJ, et al. Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med (Berl). 2020 Feb;98(2):161–177.
dc.identifier.issn1432-1440
dc.identifier.urihttps://hdl.handle.net/11351/6436
dc.descriptionIntratumor heterogeneity; Artificial intelligence; Antitumor therapeutics
dc.description.abstractIn this review, we highlight the role of intratumoral heterogeneity, focusing on the clinical and biological ramifications this phenomenon poses. Intratumoral heterogeneity arises through complex genetic, epigenetic, and protein modifications that drive phenotypic selection in response to environmental pressures. Functionally, heterogeneity provides tumors with significant adaptability. This ranges from mutual beneficial cooperation between cells, which nurture features such as growth and metastasis, to the narrow escape and survival of clonal cell populations that have adapted to thrive under specific conditions such as hypoxia or chemotherapy. These dynamic intercellular interplays are guided by a Darwinian selection landscape between clonal tumor cell populations and the tumor microenvironment. Understanding the involved drivers and functional consequences of such tumor heterogeneity is challenging but also promises to provide novel insight needed to confront the problem of therapeutic resistance in tumors.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesJournal of Molecular Medicine;98(2)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCàncer - Tractament
dc.subjectGeneracions alternants
dc.subject.meshGenetic Heterogeneity
dc.subject.meshNeoplasms
dc.subject.mesh/therapy
dc.titleClinical implications of intratumor heterogeneity: challenges and opportunities
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s00109-020-01874-2
dc.subject.decsheterogeneidad genética
dc.subject.decsneoplasias
dc.subject.decs/terapia
dc.relation.publishversionhttps://doi.org/10.1007/s00109-020-01874-2
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Ramón Y Cajal S] Grup de Patologia molecular translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Barcelona, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Sesé M, Aasen T] Grup de Patologia molecular translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Barcelona, Spain. [Capdevila C] Grup de Patologia molecular translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Department of Genetics and Development, Columbia University Medical Center, New York, NY 10032, USA. [De Mattos-Arruda L] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Diaz-Cano SJ] Department of Histopathology, King’s College Hospital and King’s Health Partners, London, UK. [Hernández-Losa J, Castellví J] Grup de Patologia molecular translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Barcelona, Spain
dc.identifier.pmid31970428
dc.identifier.wos000508697200001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/PI14%2F01320
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F02247
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/1PN/2008-2011/RD12%2F0036%2F0057
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/CB16%2F12%2F00363
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PERIS2016-2020/2017SGR1799
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F00772
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/CPII16%2F00042
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record